Served as consumer subclass counsel and steering committee member, securing a $41.5 million settlement against Merck for deceptively marketing its cholesterol drugs Vytorin and Zetia
Plaintiff(s):
Consumers and insurers who purchased or paid toward Vytorin or Zetia
Case type / claims:
Consumer fraud and product liability class action alleging that Merck & Co. falsely marketed Vytorin and Zetia as more effective than other cholesterol drugs and failed to disclose negative clinical trial results in a timely manner.
Defendant(s):
Merck & Co., Inc.
Jurisdiction:
U.S. District Court for the District of New Jersey
Year:
2010
Outcome:
- Grant & Eisenhofer secured a $41.5 million recovery for consumers and third-party payor.
- Exposed misleading marketing practices and delayed disclosure of unfavorable drug trial data.
- Strengthened pharmaceutical transparency and accountability to patients and insurers.
